EC Number   |
Activating Compound |
Reference |
|---|
   3.4.21.77 | 17-allylamine-17-demethoxygeldanamycin |
- |
708155 |
| 3.4.21.77 | androgens |
upregulation |
647332 |
| 3.4.21.77 | AUY922 |
reduces PSA concentration in a dose-dependent manner (2fold more than insulin-like growth factor-binding protein 2) and is accompanied by androgen receptor decrease |
708155 |
| 3.4.21.77 | B2-peptide |
- |
701037 |
| 3.4.21.77 | CVAYCIEHHCWTC |
- |
731135 |
| 3.4.21.77 | CVAYCIEHHCWTC |
with disulfide bridges between cysteines 1-13 and 5-10, stimulates the activity of the enzyme towards small peptide substrates, and also enhances the proteolytic activity towards protein substrates |
732770 |
| 3.4.21.77 | CVFAHNYDYLVC |
- |
731135 |
| 3.4.21.77 | CVFAHNYDYLVC |
stimulates the activity of the enzyme towards small peptide substrates, and also enhances the proteolytic activity towards protein substrates. No activation of the enzyme by the inactive derivative of peptide B2-NH2, CVFAHNADALVC, with a disulfide bridge between cysteines 1-12 |
732770 |
| 3.4.21.77 | dihydrotestosterone |
hormonal treatment of BT-474 cells with dihydrotestosterone (an androgen) for 48 h triggers an increase of prostate-specific antigen concentration in the supernatant of these cells |
708155 |
| 3.4.21.77 | insulin-like growth factor-binding protein 2 |
- |
708155 |
